Functional cure of chronic hepatitis B (CHB)—or hepatitis B surface antigen (HBsAg) loss
after 24 weeks off therapy—is now the goal of treatment, but is rarely achieved with current …

Chronic hepatitis B virus (HBV) infection is one of the high-risk factors for human HCC.
Despite the integration of virus DNA and the oncoprotein HBx, chronic necroinflammation …

Hepatocellular carcinoma (HCC) often develops following chronic hepatitis B virus (HBV)
infection and responds poorly to immune checkpoint blockade. Here, we examined the …

Adaptive immune system uses T cell receptors (TCRs) to recognize pathogens and to
consequently initiate immune responses. TCRs can be sequenced from individuals and …

Patients with chronic hepatitis B (CHB) undergoing interferon (IFN)-α-based therapies often
exhibit a poor HBeAg serological response. Thus, there is an unmet need for new therapies …

A great effort of research has been devoted in the last few years to developing new anti-HBV
therapies of finite duration that also provide effective sustained control of virus replication …

Hepatitis B virus (HBV)-specific CD8+ T cells play a dominant role during acute-resolving
HBV infection but are functionally impaired during chronic HBV infection in humans. These …

The liver's unique characteristics have a profound impact on the priming and maintenance of
adaptive immunity. This review delves into the cellular circuits that regulate adaptive …

Human T cells have a diverse T‐cell receptor (TCR) repertoire that endows them with the
ability to identify and defend against a broad spectrum of antigens. The universe of possible …

There have been unprecedented advances in the identification of new treatment targets for
chronic hepatitis B that are being developed with the goal of achieving functional cure in …